William Blair Investment Management LLC acquired a new stake in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,822,048 shares of the biopharmaceutical company’s stock, valued at approximately $48,521,000. William Blair Investment Management LLC owned approximately 2.74% of Portola Pharmaceuticals at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. SeaCrest Wealth Management LLC bought a new stake in shares of Portola Pharmaceuticals during the second quarter worth $191,000. BB&T Securities LLC bought a new stake in shares of Portola Pharmaceuticals during the second quarter worth $201,000. Smith Asset Management Group LP grew its stake in shares of Portola Pharmaceuticals by 51.1% during the third quarter. Smith Asset Management Group LP now owns 8,100 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 2,740 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Portola Pharmaceuticals during the second quarter worth $230,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of Portola Pharmaceuticals during the second quarter worth $234,000.
Shares of Portola Pharmaceuticals stock opened at $21.85 on Friday. The company has a current ratio of 6.61, a quick ratio of 6.51 and a debt-to-equity ratio of 1.21. Portola Pharmaceuticals Inc has a twelve month low of $18.18 and a twelve month high of $56.70. The firm has a market capitalization of $1.45 billion, a P/E ratio of -4.54 and a beta of 2.04.
A number of analysts have weighed in on PTLA shares. Zacks Investment Research raised shares of Portola Pharmaceuticals from a “hold” rating to a “buy” rating and set a $27.00 target price on the stock in a research note on Thursday, October 11th. ValuEngine cut shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, August 13th. Oppenheimer set a $60.00 target price on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 10th. BidaskClub cut shares of Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 22nd. Finally, William Blair reaffirmed a “buy” rating on shares of Portola Pharmaceuticals in a research note on Monday, August 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the stock. Portola Pharmaceuticals presently has an average rating of “Buy” and an average target price of $37.50.
ILLEGAL ACTIVITY WARNING: “1,822,048 Shares in Portola Pharmaceuticals Inc (PTLA) Acquired by William Blair Investment Management LLC” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2018/12/02/1822048-shares-in-portola-pharmaceuticals-inc-ptla-acquired-by-william-blair-investment-management-llc.html.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.
Featured Story: How are the companies in the S&P 500 selected?
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.